Patent dispute: Delhi High Court gives a boost to access to affordable medicines
AffiliationMedecins Sans Frontieres-Campaign for Access to Essential Medicines, C 236 Defence Colony, New Delhi, India
MetadataShow full item record
JournalIndian Journal of Medical Ethics
AbstractThe Delhi High Court has rejected the petition filed by Bayer Corporation seeking to stop the Drugs Controller of India (DCGI) from registering a generic version of a patented cancer drug. The case was filed in 2008 by Bayer to try and introduce "patent linkage" which involves linking the registration (marketing approval) of drugs with their patent status. If Bayer's plea for "patent linkage" had been accepted by the court, it would have undermined public health safeguards contained in India's patent legislation. This comment discusses the Bayer case in the context of efforts by multinational pharmaceutical companies to introduce barriers to generic competition, the only proven means of reducing the prices of medicines to make them affordable to those in need. Bayer has filed an appeal in the Supreme Court, indicating that it does not intend to give up.
PublisherForum for Medical Ethics Society
- Access to medicine and the dangers of patent linkage: lessons from Bayer Corp v. Union of India.
- Authors: Tsui M
- Issue date: 2011 Mar
- Is India ready to lead the battle for fair access to medicines?
- Authors: Lancet Oncology
- Issue date: 2013 May
- Novartis challenges India's drug patent laws in Supreme Court.
- Authors: Billingsley M
- Issue date: 2012 Feb 21
- India's patent laws under pressure.
- Authors: Roderick P, Pollock AM
- Issue date: 2012 Sep 15
- Taking TRIPS to India--Novartis, patent law, and access to medicines.
- Authors: Mueller JM
- Issue date: 2007 Feb 8